Dr. Parker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
Yale-New Haven Hospital
New Haven, CT 06510Phone+1 203-200-4363Fax+1 203-785-4116
Summary
- Dr. Terri Parker is an oncologist in New Haven, CT and is affiliated with Yale-New Haven Hospital. She received her medical degree from St. George's University School of Medicine and has been in practice 12 years. She specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, and multiple myeloma.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Uconn School Of Medicine2008 - 2009- University of ConnecticutResidency, Internal Medicine, 2005 - 2008
St. George's University School of MedicineClass of 2005
Certifications & Licensure
CT State Medical License 2008 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- David S. Fischer Teaching Award for Outstanding Faculty Teaching and Mentoring of Fellows in Medical Oncology Yale Cancer Center, 2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma Start of enrollment: 2012 Nov 01
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Dec 06
- An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma Start of enrollment: 2016 Aug 10
- Join now to see all
Publications & Presentations
PubMed
- 392 citationsOral selinexor-dexamethasone for triple-class refractory multiple myelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew Yee
The New England Journal of Medicine. 2019-08-21 - 621 citationsDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau
The New England Journal of Medicine. 2019-05-29 - 113 citationsEarly alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie, Mahesh Shrestha, Katherine E. Pendleton
JCI Insight. 2019-06-06
Abstracts/Posters
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...Terri L Parker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceTerri L Parker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cutaneous toxicity of pralatrexate in cutaneous and peripheral T-cell lymphomaParker TL, Barbarotta L, Girardi M, and Foss F., American Society of Hematology Annual Meeting, Atlanta, GA, 12/2012
Committees
- Member, Scientific Protocol Review Committee at Smilow Cancer Hospital 2015 - Present
- Member, Laboratory Formulary Committee at Yale New Haven Hospital 2014 - Present
- Member, Smilow Ambulatory Care Committee 2013 - Present
- Member, Transfusion and Tissue Banking Committee at Yale New Haven Hospital 2013 - Present
- Member, Faculty Advisory Committee at Yale School of Medicine 2015 - 2017
Professional Memberships
- Member
- Member
- Member
- International Society of AmyloidosisMember
- International Myeloma SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
